The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
News|Articles|February 9, 2004
The new health and beauty care standouts of 2003
Hamacher renders its decision on which OTCs/HBCs introduced in 2003 were the hits of the year
Advertisement
Advertisement
Related to this article
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Improve Access, Safe Use of Obesity Medications
2
FDA Approves New Drug for HSV Lesions in Adults
3
Is Your Independent Pharmacy Ready for New Therapies and Innovations?
4
Wearable Tech as a Revenue, Clinical Service Opportunity for Pharmacists | NCPA 2026
5